{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105441","form_type":"8-K","ticker":"TEM","cik":"0001717115","company_name":"Tempus AI, Inc.","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.763977+00:00","generated_at":"2026-05-17T16:41:32.708821+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tempus AI Q2 rev $315M (+90% YoY); raises FY25 guidance to $1.26B, adj EBITDA $5M","bullets":["Revenue $314.6M (+89.6% YoY); genomics up 115% to $241.8M; data/services +35.7% to $72.8M.","Gross profit $195.0M (+158% YoY); net loss improved to ($42.8M) from ($552.2M); adj EBITDA ($5.6M) vs ($31.2M).","Issued $750M 0.75% convertible notes; cash $293M; FY guidance raised: rev ~$1.26B, adj EBITDA $5M.","Oncology testing volume +26% YoY; hereditary +32%; >212,000 NGS tests delivered in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105441","json":"https://secwatch.observer/filing/0000950170-25-105441.json","markdown":"https://secwatch.observer/filing/0000950170-25-105441.md","text":"https://secwatch.observer/filing/0000950170-25-105441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1717115/000095017025105441/0000950170-25-105441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1717115/000095017025105441/tem-20250808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:41:32.708821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}